LRRK2 parkinsonism is broadly similar to “idiopathic” disease in clinical manifestations and age at onset (AAO), generating interest in its potential as a therapeutic target with broader application to PD (Di Maio et al., 2018). This evidence concerns the gene LRRK2 and Parkinsonism.